

19 APRIL 2021

SUPPLEMENT TO THE GSSP BASE PROSPECTUS 16

SUPPLEMENT 2/2020



BARCLAYS BANK IRELAND PLC
(Incorporated with limited liability in Ireland)

Pursuant to the Global Structured Securities Programme

Introduction

This supplement dated 19 April 2021 (the "**Supplement**") is supplemental to, and must be read in conjunction with, the GSSP Base Prospectus 16 (the "**Base Prospectus**") which is constituted by the registration document (the "**Registration Document**") dated 15 April 2021 and the Securities Note dated 27 August 2020 (as supplemented by Supplement 1/2020 dated 17 February 2021 ("**Supplement 1/2020**"), the "**Base Prospectus 16 Securities Note**") all as prepared by Barclays Bank Ireland PLC in its capacity as issuer (the "**Issuer**") in respect of its Global Structured Securities Programme (the "**Programme**").

The Registration Document may be inspected during normal business hours at the registered office of the Issuer or at <https://home.barclays/investor-relations/fixed-income-investors/prospectus-and-documents/structured-securities-prospectuses/bbi-structured-securities-prospectuses/#regdoc>.

This Supplement constitutes a supplement in respect of the Base Prospectus for the purposes of Article 23 of Regulation (EU) 2017/1129 (as amended, the "**EU Prospectus Regulation**"). This Supplement has been approved as a supplementary prospectus by the Central Bank of Ireland (the "**CBI**") as competent authority under the EU Prospectus Regulation. The CBI only approves this Supplement as meeting the standards of completeness, comprehensibility and consistency imposed by the EU Prospectus Regulation. Such approval should not be considered as an endorsement of the Issuer or the quality of the securities (the "**Securities**") that are the subject of this Supplement. Investors should make their own assessment as to the suitability of investing in the Securities.

Terms defined in the Base Prospectus 16 Securities Note shall, unless the context otherwise requires, have the same meanings when used in this Supplement.

References to the Base Prospectus shall hereafter mean the Base Prospectus as supplemented by this Supplement. The Issuer accepts responsibility for the information contained in this Supplement. To the best of the knowledge of the Issuer, the information contained in this Supplement is in accordance with the facts and this Supplement makes no omission likely to affect its import. Save as disclosed in this Supplement, no significant new factor, material mistake or inaccuracy relating to the information included in the Base Prospectus is capable of affecting the assessment of securities issued pursuant to the Base Prospectus has arisen or been noted, as the case may be, since the publication of the Base Prospectus (as supplemented at the date hereof) by the Issuer.

Purpose

The purpose of this Supplement is to update certain information on the front cover pages and in each of the "*Important Information*", "*Risk Factors*" and "*Form of Final Terms*" sections of the Base Prospectus 16 Securities Note in light of the replacement of the Issuer's registration document dated 27 May 2020 (as supplemented on 4 August 2020) with the Registration Document dated 15 April 2021.

Updates, amendments and supplements

A) Amendments to the front cover pages

The subsection entitled "*What is the Registration Document?*" on the front cover pages of the Base Prospectus 16 Securities Note shall be amended by deleting the subsection entitled "*What is the Registration Document?*" (as supplemented by Supplement 1/2020) on page 1 in its entirety and replacing it with the following:

"What is the Registration Document?"

The Issuer's registration document dated 15 April 2021 (as may be supplemented and/or replaced from time to time, the "**Registration Document**") has been approved by the Central Bank of Ireland (the "**CBI**") pursuant to the EU Prospectus Regulation. The Registration Document provides a description of the Issuer's business activities as well as certain financial information and material risks faced by the Issuer. The Registration Document and the supplements thereto are available for viewing at: <https://home.barclays/investor-relations/fixed-income-investors/prospectus-and-documents/structured-securities-prospectuses/bbi-structured-securities-prospectuses/#regdoc> and <https://home.barclays/investor-relations/fixed-income-investors/prospectus-and-documents/structured-securities-prospectuses/bbi-structured-securities-prospectuses/#regdocsupplement>".

B) Amendments to the section entitled "Important Information"

The section entitled "*Important Information*" on pages 4 to 8 of the Base Prospectus 16 Securities Note shall be amended by deleting the subsection entitled "*Ratings*" and the footnotes inserted by Supplement 1/2020 on page 8 in their entirety.

C) Amendments to the section entitled "Risk Factors"

The section entitled "*Risk Factors*" on pages 12 to 39 of the Base Prospectus 16 Securities Note shall be amended by deleting the second paragraph following the subsection heading "*Risk Factors Relating to the Issuer and the Barclays Bank Group*" on page 13 in its entirety and replacing it with the following:

"The Issuer's principal activities are the provision of corporate and investment banking services to EU corporate entities, retail banking services in Germany and Italy and private banking services to EU clients and, as such, faces a variety of risks that are substantial and inherent in its businesses. These risks are described in the section '*Risk Factors*' on pages 6 to 23 of the Registration Document."

D) Amendments to the section entitled "Form of Final Terms"

The section entitled "*Form of Final Terms*" on pages 63 to 84 of the Base Prospectus 16 Securities Note shall be amended by deleting the first opening paragraph immediately under the securities heading on page 63 (as supplemented by Supplement 1/2020) of the Base Prospectus 16 Securities Note in its entirety and replacing it with the following text:

"This document constitutes the final terms of the Securities (the "**Final Terms**") described herein [for the purposes of Article 8 of [the EU Prospectus Regulation] [Regulation (EU) 2017/1129 (as amended, the "**EU Prospectus Regulation**")]]¹ [for the purposes of Article 8 of [the UK Prospectus Regulation] [Regulation (EU) 2017/1129 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (as amended) and regulations made thereunder (as amended, the "**UK Prospectus Regulation**")]]² and is prepared in connection with the Global Structured Securities Programme established by Barclays Bank Ireland PLC (the "**Issuer**"). These Final Terms complete and should be read in conjunction with GSSP Base Prospectus 16 which constitutes a base prospectus drawn up as separate documents (including the Registration Document

dated 15 April 2021 [as supplemented on [●] [,][and] [●]] and the Securities Note relating to the GSSP Base Prospectus 16 dated 27 August 2020 [as supplemented on 17 February 2021[,][and] 15 April 2021 [●] [and [●]]] [for the purposes of Article 8(6) of the [EU Prospectus Regulation] [UK Prospectus Regulation]] (the "**Base Prospectus**"). Full information on the Issuer and the offer of the Securities is only available on the basis of the combination of this Final Terms and the Base Prospectus. A summary of the individual issue of the Securities is annexed to this Final Terms.

1, Only include the language in square brackets if the Final Terms are prepared for the purposes of the EU Prospectus Regulation.

2. Only include the language in square brackets if the Final Terms are prepared for the purposes of the UK Prospectus Regulation."

To the extent that there is any inconsistency between (a) any statement in this Supplement (in relation to the Base Prospectus) and (b) any other statement in, or incorporated by reference in the Base Prospectus, the statements in (a) above shall prevail.

In accordance with Article 23(2a) of the EU Prospectus Regulation, investors who have already agreed to purchase or subscribe for securities pursuant to the Base Prospectus before this Supplement is published have the right, exercisable within three working days after the publication of this Supplement, to withdraw their acceptances, provided that the significant new factor, material mistake or material inaccuracy to which this Supplement relates arose or was noted before the closing of the offer period or the delivery of the securities, whichever occurs first. Investors may contact the relevant distributor of such securities in connection therewith should they wish to exercise such right of withdrawal. The final date of such right of withdrawal is 22 April 2021.



The date of this Supplement is 19 April 2021